Cancer drugs that speed onto the market based on encouraging preliminary studies often don’t show clear benefits when more careful follow-up trials are done, according to research published Tuesday

Quick Read

Researchers have analysed anonymized phone records of tens of millions of people in low-income countries. Critics question whether the benefits outweigh the risks

Quick Read

A fertility clinic in Dubai emailed He Jiankui on December 5 — just a week after he announced the births — asking if he could teach its clinicians “CRISPR gene editing for Embryology Lab Application.”

Quick Read

In 16th- and 17th-century Europe, physicians, butchers, and executioners alike hawked the salutary effects of Axungia hominis

Quick Read

Trials of vaccines and treatments have not included enough female participants. Now that scientists are exploring possible cures, the need to enroll women is greater than ever

Quick Read

Aaron Troy writes, “Trump administration recently finalized a rule that will require drug makers to show a medication’s list price. As a future physician, I am against this change. Adding the information would make the ads less helpful and more confusing for patients, who are powerless to change the complex system…”

Quick Read

It barred the FDA from considering any clinical trial application “in which a human embryo is intentionally created or modified to include a heritable genetic modification.” Although a different “rider” bars the NIH from funding human germline editing—or the genetic modification of sperm, eggs, or embryos

Quick Read

The military is constantly using technology to build better ships, warplanes, guns and armor. Shouldn’t it also use drugs to build better soldiers?

Quick Read